Emergence of Medical Affairs Executives as Enterprise-Level Leaders

Medical affairs is at an inflection point. Once viewed primarily as an evidence generation medical support function, it’s now being asked to play a far more strategic role in shaping markets and KOL mindsets prior to launch—collaborating closely in partnership with both development and commercial in launch preparation, and ensuring innovation translates into meaningful patient impact, all while remaining firmly grounded in compliance and scientific integrity. Today’s medical affairs leaders are being brought into the conversation much earlier, priming the market for new launches.

To better understand how this transformation from medical education and scientific exchange to strategic partner is unfolding, Russell Reynolds Associates spoke with senior medical affairs leaders from some of the most innovative pharmaceutical companies in the industry. Their perspectives reveal a function that is redefining its value through deeper business partnership, a sharper focus on quality and outcomes, the accelerating use of digital and AI, and a new leadership profile built for complexity.

What follows are four key insights from these leaders and our work in this space, and what it will take to lead the function forward.

Medical affairs is now a core enterprise partner

Medical affairs functions are undergoing a fundamental shift. Leaders are now operating as true enterprise business partners who shape both treatment adoption, patient outcomes and differentiating products in competitive market landscapes. Today, medical affairs plays an active role in translating complex science into strategically relevant insights that inform launch readiness, access strategy, clinical adoption, and lifecycle decision-making, while remaining firmly grounded in scientific integrity and compliance. Its distinct value lies in connecting controlled clinical trial data with real-world evidence and unmet patient needs, generating actionable insights that influence how therapies are understood, positioned, and appropriately used in practice.

As healthcare systems become more decentralized and digitally enabled, the credibility and neutrality of medical affairs uniquely position the function to engage trusted stakeholders, ranging from policymakers and medical societies to multidisciplinary care teams, in ways that advance both patient care and organizational objectives. Increasingly, medical affairs leaders are expected to pair deep scientific expertise with commercial acumen, digital fluency, and an enterprise mindset, enabling them to anticipate market dynamics, shape evidence strategy, and guide cross-functional decision-making.

AI and advanced analytics are further accelerating this evolution, enhancing insight generation, enabling more targeted engagement, and increasing the function’s strategic impact across the value chain. In this new model, medical affairs is no longer simply the connective tissue of biopharma; it’s an essential value driver, ensuring that innovation translates into meaningful patient benefit in increasingly  competitive markets.

 

"Medical affairs isn’t just there to provide education or to support commercial. It really is a unique function that provides critical bridging evidence that fills the gap between clinical trials and real-world patient care."

Medical Affairs leader at a top five large-cap global biopharma company

---

"The role of medical has transitioned into being the ultimate custodian of the patient voice—helping shape launch sequencing and how physicians will use the medicine to the best effect and best outcome for patients."

Medical Affairs leader at a top ten large-cap global biopharma company

 

Success is being redefined around medical care influence and patient impact

As disease areas become increasingly competitive, early involvement of medical affairs is critical to differentiating therapies with physicians through peer-to-peer interactions and before prescribing behaviors and treatment paradigms are established. Virtual engagement has expanded access to physicians and prescribers—an advantage particularly meaningful for smaller biotechs—allowing medical teams to shape clear, credible scientific narratives that help clinicians understand how new data translate into meaningful clinical value. In an era defined by complex, crowded specialty markets, medical affairs plays a pivotal role in influencing how emerging therapies are positioned, understood, and considered as potential new standards of care.

This redefinition of success has resulted in a shift in measurement. Medical affairs now decisively emphasizes quality over quantity of interactions with medical providers and patients, enabled by digital tools, data, and analytics that allow teams to assess and visualize real impact. Traditional metrics—such as counting MSL visits or publications—are being replaced by measures that evaluate knowledge transfer, behavioral change, and improvements in clinical practice. Quality engagement means tailoring communication to stakeholder needs, diagnosing local practice gaps, and co-creating solutions that improve patient outcomes. By leveraging data to identify trends, personalize education, and demonstrate real-world value across systems, medical affairs is redefining success around influence, credibility, and patient benefit rather than activity volume—asserting itself as a strategic pillar of biopharma’s value chain.

 

"The old model counted the number of conversations an MSL was having; metrics were about quantity. Now, we want the MSL to understand who is driving decisions, where the gaps are in patient needs, and to bring the right evidence or education to support the barrier or gap in a given organization. There’s been a move away from quantity of interactions to quality of interactions."

Medical Affairs leader at a top five large-cap global biopharma company

 

AI and digital technologies are transforming medical affairs into a data-driven intelligence function

Digital innovation and AI are transforming medical affairs from an insight-gathering function into a data-driven strategic partner. Across organizations, AI is being used to analyze real-world data, generate insights, and streamline content creation, dramatically improving speed,  and efficiency, and cost. Tools like ChatGPT are enabling field teams to prepare for scientific engagements, synthesize insights from advisory boards, and personalize communications at scale.

Beyond automation, it’s enhancing decision-making and evidence generation efforts, helping teams identify unmet needs and measure clinical impact more precisely. AI also supports the creation of tailored educational materials and improves access to complex information for healthcare professionals. However, success depends on fostering a digital mindset: encouraging curiosity, experimentation, and cross-functional collaboration rather than just implementing tools.

Leaders now view the digital mindset as a core competency in medical affairs, on par with scientific and strategic acumen. As AI matures, medical affairs is poised to become the intelligence hub of biopharma, linking science, data, and technology to drive smarter, faster, and more impactful healthcare decisions.

 

"AI is embedded in everything we do now, from prep calls for field medical to advisory board summaries to content generation. Things that took two weeks now take two hours."

Medical Affairs leader at a public, commercial-stage mid-cap biotech company

---

"AI should be an enabler. It takes work out of the system, consolidates information, and generates insights. But you are still going to need the strategists who are going to understand where the market is today, where it is moving in the future, and the ability to draw upon their experiences to understand how that can translate into a strategy."

Medical Affairs leader at a public, commercial-stage mid-cap biotech company

---

"You do not need people who are technical experts in AI, but people who understand the possibility of what can be created. They can imagine what’s possible and apply it to patient and physician needs."

Medical Affairs leader at a top ten large-cap global biopharma company

 

The future of medical affairs belongs to those who can command the cross-functional conversation

The next generation of medical affairs leadership is defined less by traditional credentials (such as PhD or MD) and more by enterprise mindset, strategic influence, and the ability to operate credibly at the intersection of science and business. Today’s leaders are expected to pair deep medical expertise with a sophisticated understanding of the competitive landscape, commercial priorities, how medicines are launched, accessed, adopted, and sustained, while maintaining the independence and integrity that underpin medical credibility. This evolution requires medical leaders who can translate clinical insight into enterprise-relevant guidance, shaping evidence strategy, informing portfolio and lifecycle decisions, and influencing go-to-market execution without crossing compliance boundaries.

The industry’s top medical affairs leaders communicates fluently across R&D, commercial, market access, and external stakeholders to align medical narratives with organizational strategy and real-world care delivery. Emotional intelligence, curiosity, and adaptability are now as critical as medical expertise, particularly in complex, fast-moving environments where medical is increasingly asked to help solve business-critical problems. High-performing leaders are intentionally building cultures that encourage constructive debates, cross-functional collaboration, and disciplined experimentation, replacing risk aversion with thoughtful, compliant innovation. Many organizations are now seeking medical leaders with diverse career paths, recognizing that broader exposure strengthens enterprise-wide medical thinking and strategic judgment.

Historically, medical affairs leaders have built their careers within this functional silo; however, we now see more medical leaders completing rotations in commercial functions and as program development leads to round out their exposure across a variety of functional areas. Talent development has similarly shifted toward building capabilities in strategic communication, digital engagement, and implementation science, equipping teams to drive measurable patient outcomes while supporting sustainable commercial success. Ultimately, modern medical affairs leadership is about thinking beyond the function, helping inform enterprise direction, strengthening the integration of science into decision-making, and leading transformation from within.

 

"Modern medical affairs leaders need to be able to shift their communication styles between the business world— where communication is succinct and direct, and the scientific world—where things needs to be explained from a methodological standpoint. The most successful leaders are able to go between those two skillsets, but it’s one of the toughest things to teach people."

Medical Affairs leader at a top five large-cap global biopharma company

---

"The phenotype of a medical affairs professional today is someone who is strategic, impact-focused, and able to work across the enterprise."

Medical Affairs leader at a public, commercial-stage mid-cap biotech company

 

For companies seeking to hire next-generation medical affairs leaders, prioritize enterprise-minded executives who can balance scientific integrity with a clear understanding of commercial realities and actively shape organizational strategy. The most effective leaders adapt their communication across increasingly complex internal and external stakeholder landscapes and often bring diverse, non-traditional career paths that strengthen strategic judgment and influence. To fully unlock the value of medical affairs, organizations must also empower these leaders with a true seat at the table; integrating medical leadership into both R&D and business unit decision-making, and positioning the function as a co-owner of both clinical and commercial strategy.

Authors

Cameron Findlater is a member of Russell Reynolds Associates’ Healthcare Knowledge team. He is based in New York.
Yvonne Lu co-leads Russell Reynolds Associates’ Global Biopharma practice. She is based in San Francisco.
Eric Wimpfheimer is a member of Russell Reynolds Associates’ Biopharma practice. He is based in New York.